Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Immunome ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Immunome's ebitda for the twelve months ending Mar 31, 2026 was -$236.35M. For fiscal 2025 it was -$221.65M. The highest annual figure on record is -$9.73M in fiscal 2019.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$221.65M	–
FY2024	Dec 31, 2024	-$304.23M	–
FY2023	Dec 31, 2023	-$109.07M	–
FY2022	Dec 31, 2022	-$36.48M	–
FY2021	Dec 31, 2021	-$24.45M	–
FY2020	Dec 31, 2020	-$11.51M	–
FY2019	Dec 31, 2019	-$9.73M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q1 FY2026	Mar 31, 2026	-$58.73M	–
Q4 FY2025	Dec 31, 2025	-$72.23M	–
Q3 FY2025	Sep 30, 2025	-$59.55M	–
Q2 FY2025	Jun 30, 2025	-$45.84M	–
Q1 FY2025	Mar 31, 2025	-$44.03M	–
Q4 FY2024	Dec 31, 2024	-$82.52M	–
Q3 FY2024	Sep 30, 2024	-$50.11M	–
Q2 FY2024	Jun 30, 2024	-$39.46M	–
Q1 FY2024	Mar 31, 2024	-$132.14M	–
Q4 FY2023	Dec 31, 2023	-$94.50M	–
Q3 FY2023	Sep 30, 2023	-$4.52M	–
Q2 FY2023	Jun 30, 2023	-$5.67M	–
Q1 FY2023	Mar 31, 2023	-$4.38M	–
Q4 FY2022	Dec 31, 2022	-$7.69M	–
Q3 FY2022	Sep 30, 2022	-$8.43M	–
Q2 FY2022	Jun 30, 2022	-$8.81M	–
Q1 FY2022	Mar 31, 2022	-$11.54M	–
Q4 FY2021	Dec 31, 2021	-$7.73M	–
Q3 FY2021	Sep 30, 2021	-$7.44M	–
Q2 FY2021	Jun 30, 2021	-$5.57M	–
Q1 FY2021	Mar 31, 2021	-$3.72M	–
Q4 FY2020	Dec 31, 2020	-$3.82M	–
Q3 FY2020	Sep 30, 2020	-$2.64M	–
Q2 FY2020	Jun 30, 2020	-$2.56M	–
Q1 FY2020	Mar 31, 2020	-$2.49M	–
Q4 FY2019	Dec 31, 2019	-$2.73M	–